Abstract
Immunodeficiency-associated lymphoproliferative disorders (LPDs) can occur in the setting of HIV infection, after transplantation (posttransplant lymphoproliferative disorder, PTLD), or in other clinical conditions including primary immunodeficiency or the use of immunosuppressive drugs (iatrogenic immunodeficiency-associated LPD). LPDs in the setting of immunodeficiency share similar morphologic features, with a broad spectrum of findings from polymorphous lymphoplasmacytic proliferations to aggressive lymphoma. In patients diagnosed with an immunodeficiency-associated LPD, a staging bone marrow is recommended as part of the initial workup. This chapter illustrates the common bone marrow findings in immunodeficiency-associated LPD.
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
- Immunodeficiency-associated lymphoproliferative disorder
- Posttransplant
- HIV
- Iatrogenic immunodeficiency
- Bone marrow involvement
Immunodeficiency-associated lymphoproliferative disorders (LPDs) can occur in the setting of HIV infection, after transplantation (posttransplant lymphoproliferative disorder, PTLD), or in other clinical conditions including primary immunodeficiency or the use of immunosuppressive drugs (iatrogenic immunodeficiency-associated LPD). LPDs in the setting of immunodeficiency share similar morphologic features, with a broad spectrum of findings from polymorphous lymphoplasmacytic proliferations to aggressive lymphoma. In patients diagnosed with an immunodeficiency-associated LPD, a staging bone marrow is recommended as part of the initial workup.
Lymphoproliferative Disorders in HIV Patients
LPDs in HIV patients are heterogeneous and range from polyclonal hyperplastic lesions to aggressive lymphomas. At one end of the spectrum are the early and polymorphic lesions that typically show a heterogeneous cellular proliferation composed of small lymphocytes, plasma cells, and immunoblasts resembling polymorphic PTLD (Fig. 8.1). Bone marrow involvement by early and polymorphic LPDs may show features overlapping with reactive changes commonly seen in HIV-infected patients. The frequency of early and polymorphic LPDs in HIV patients is unknown, but they seem much less common than in the PTLD setting. At the other end of the spectrum is HIV-associated lymphoma, which includes lymphomas also occurring in immunocompetent patients , such as diffuse large B-cell lymphoma, Burkitt lymphoma , and Hodgkin lymphoma , as well as lymphomas occurring much more commonly in HIV patients, such as primary effusion lymphoma and plasmablastic lymphoma. HIV-associated lymphomas are usually aggressive and often spread to the bone marrow; in some cases, the bone marrow may be the primary or initial diagnostic site (Figs. 8.2, and 8.3) [1, 2]. The morphologic features of HIV-associated lymphomas are similar to their counterparts in the immunocompetent population, but Epstein-Barr virus (EBV) is more often positive. HIV-related Hodgkin lymphoma, for example, is almost always associated with EBV [3]. The reported frequency of bone marrow involvement by HIV-related lymphoma varies. In one of the largest series, the German HIV Lymphoma Cohort reported bone marrow involvement in 25 (16%) of 154 diffuse large B-cell lymphomas, 32 (31%) of 103 Burkitt lymphomas, and 6 (18%) of 34 plasmablastic lymphomas [4]. Primary effusion lymphoma almost always occurs in immunodeficient patients, with universal association with human herpesvirus 8 (HHV8) infection and common EBV coinfection, but bone marrow involvement is uncommon (11%) [5]. The features of bone marrow involvement by HIV-associated LPD are summarized in Table 8.1.
Posttransplant Lymphoproliferative Disorders
PTLD comprises another major group of immunodeficiency-associated LPDs and includes four categories based on the current WHO classification: early lesions, polymorphic PTLD, monomorphic PTLD (B- and T-cell lymphomas), and classical Hodgkin lymphoma (Table 8.2). The frequency of bone marrow involvement by PTLDs after solid organ transplant varies from 14% to 40% [6,7,8,9,10,11,12,13]; monomorphic (23.5%) and polymorphic (15.7%) types predominate [13]. The bone marrow involvement by monomorphic PTLD can be either B-cell or T-cell type (Fig. 8.4) [13]. Among all types of monomorphic PTLDs involving the bone marrow, diffuse large B-cell lymphoma is the most common, but other types such as Burkitt lymphoma, plasmacytoma-like lesions, plasma cell myeloma, and rare NK/T-cell lymphoma have also been reported) (Figs. 8.5, 8.6, 8.7, and 8.8) [13]. Neither EBV status, based on in situ hybridization for EBV-encoded RNA (EBER), nor the type of organ transplanted is statistically significant in predicting the presence or absence of bone marrow involvement [13]. The morphologic findings of bone marrow involvement by PTLD vary from lymphoid aggregates, interstitial infiltration, and increased plasma cells to architectural, destructive lesions consisting of sheets of atypical lymphocytes [13,14,15]. The bone marrow involvement by early lesions or polymorphic PTLD can be subtle and may overlap with reactive or infectious conditions. The positive EBER is seen in scattered hematopoietic cells or in aggregates, co-localized with lymphocytes, plasmacytoid lymphocytes, or plasma cells [14]. In cases with subtle morphologic findings such as small lymphoid aggregates and mild plasmacytosis, the presence of rare EBER-positive cells could be expected in posttransplant immunodeficiency; this is not considered definitive evidence of bone marrow involvement by PTLD [14]. However, the presence of cytologic atypia, extensive necrosis or increased large transformed cells, and detection of clonality or chromosomal aberrancies favor a lymphoproliferative process [14, 16]. The morphologic findings of monomorphic PTLD are similar to the corresponding lymphoma occurring in immunocompetent patients; the bone marrow involvement ranges from subtle interstitial infiltrates highlighted by immunohistochemistry to overt nodular or diffuse infiltrates [13, 15].
Iatrogenic Immunodeficiency-Related Disorders
Analogous to what has been observed in PTLDs, iatrogenic immunodeficiency-associated LPDs may occur in patients with rheumatologic diseases or inflammatory conditions treated with immune modulatory drugs (Fig. 8.9). Immunodeficiency-associated LPDs arising in clinical settings other than transplantation are morphologically similar to PTLDs, though extranodal involvement is frequent and bone marrow involvement is uncommon [17, 18]. Overall, the information regarding bone marrow involvement by immunodeficiency-associated LPDs in non-transplant patients is limited.
References
Corti M, Villafane M, Minue G, Campitelli A, Narbaitz M, Gilardi L. Clinical features of AIDS patients with Hodgkin’s lymphoma with isolated bone marrow involvement: report of 12 cases at a single institution. Cancer Biol Med. 2015;12:41–5.
Ponzoni M, Fumagalli L, Rossi G, Freschi M, Re A, Vigano MG, et al. Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma. Mod Pathol. 2002;15:1273–8.
Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol. 2007;14:189–94.
Schommers P, Hentrich M, Hoffmann C, Gillor D, Zoufaly A, Jensen B, et al. Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. Br J Haematol. 2015;168:806–10.
Boulanger E, Agbalika F, Maarek O, Daniel MT, Grollet L, Molina JM, et al. A clinical, molecular and cytogenetic study of 12 cases of human herpesvirus 8 associated primary effusion lymphoma in HIV-infected patients. Hematol J. 2001;2:172–9.
Morrison VA, Dunn DL, Manivel JC, Gajl-Peczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med. 1994;97:14–24.
Maecker B, Jack T, Zimmermann M, Abdul-Khaliq H, Burdelski M, Fuchs A, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;25:4902–8.
Dotti G, Fiocchi R, Motta T, Mammana C, Gotti E, Riva S, et al. Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. Transplantation. 2002;74:1095–102.
Muti G, Cantoni S, Oreste P, Klersy C, Gini G, Rossi V, et al. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica. 2002;87:67–77.
Akar Ozkan E, Ozdemir BH, Yilmaz Akcay E, Terzi A, Karakus S, Haberal M. Bone marrow involvement by lymphoproliferative disorders after solid-organ transplant. Exp Clin Transplant. 2015;13(Suppl 1):183–7.
Hourigan MJ, Doecke J, Mollee PN, Gill DS, Norris D, Johnson DW, et al. A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation. Br J Hematol. 2008;141:904–7.
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009;27:3354–62.
Montanari F, O’Connor OA, Savage DG, Zain JM, Venkatraman S, McCormick EK, et al. Bone marrow involvement in patients with posttransplant lymphoproliferative disorders: incidence and prognostic factors. Hum Pathol. 2010;41(8):1150.
Koeppen H, Newell K, Baunoch DA, Vardiman JW. Morphologic bone marrow changes in patients with posttransplantation lymphoproliferative disorders. Am J Surg Pathol. 1998;22:208–14.
Perry AM, Aoun P, Coulter DW, Sanger WG, Grant WJ, Coccia PF. Early onset, EBV(−) PTLD in pediatric liver–small bowel transplantation recipients: a spectrum of plasma cell neoplasms with favorable prognosis. Blood. 2013;121:1377–83.
Frizzera G, Hanto DW, Gajl-Peczalska KJ, Rosai J, McKenna RW, Sibley RK, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res. 1981;41:4262–79.
Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol. 1996;14:1943–9.
Hoshida Y, JX X, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol. 2007;34:322–31.
Baptista MJ, Garcia O, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, et al. HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era. AIDS. 2015;29:811–8.
Raphael M, Said J, Borisch B, Cesarman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Publications Center; 2008. p. 340–2.
Koizumi Y, Uehira T, Ota Y, Ogawa Y, Yajima K, Tanuma J, et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol. 2016;104:669–81.
Loghavi S, Alayed K, Aladily TN, Zuo Z, Ng SB, Tang G, et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol. 2015;8:65.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gao, J., Chen, YH. (2018). Immunodeficiency-Associated Lymphoproliferative Disorder. In: George, T., Arber, D. (eds) Atlas of Bone Marrow Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7469-6_8
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7469-6_8
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-7467-2
Online ISBN: 978-1-4939-7469-6
eBook Packages: MedicineMedicine (R0)